Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans-Reference-Cited by-同舟云学术

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans

Published:2012-07-11 Issue:9 Volume:83 Page:894-902
ISSN:0022-3050
Container-title:Journal of Neurology, Neurosurgery & Psychiatry
language:en
Short-container-title:J Neurol Neurosurg Psychiatry

Author:

Maccecchini Maria L,Chang Mee Young,Pan Catherine,John Varghese,Zetterberg Henrik,Greig Nigel H

Publisher

BMJ

Subject

Psychiatry and Mental health,Neurology (clinical),Surgery

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease;Alzheimer's Research & Therapy;2024-07-05

2. APP dyshomeostasis in the pathogenesis of Alzheimer’s disease: implications for current drug targets;Alzheimer's Research & Therapy;2024-06-29

3. Comparative Analysis of Posiphen Pharmacokinetics across Different Species—Similar Absorption and Metabolism in Mouse, Rat, Dog and Human;Biomolecules;2024-05-15

4. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer’s Disease;2024-03-22

5. RNA–Small-Molecule Interaction: Challenging the “Undruggable” Tag;Journal of Medicinal Chemistry;2024-03-18